Home Page
Medical Device Forum panel discusses regulatory, supply chain challenges
“Navigating Regulatory and Supply Chain Challenges Today and Tomorrow” was the topic of the May 16 NCBIO Medical Device Luncheon and Forum held at the N.C Biotechnology Center.
The discussion was moderated by Eric Hill, senior director, scientific and technical services for Boston Analytical. The event was sponsored by Clancy & Theys Construction Company, Hughes Pittman & Gupton, Mercury Business Services, UniClean Cleanroom Services and YourBio Health.
To start off, the panelists gave an overview of what was currently happening and most relevant to them in their working environment.
Read MorePanelists offer advice on funding options for emerging companies
Panelists at the NCBIO Emerging Companies Luncheon and Forum held Wednesday, March 22, at the NC Biotechnology Center offering insight into the way their organizations choose investments, when to seek SBIR funding, engaging with a funding agency for the first time and more.
The forum was sponsored by Clancy & Theys Construction Company, JBK Associates International, Nikon and SAS.
The panel was moderated by Kseniya Simpson, Ph.D., associate, Hatteras Venture Partners.
Read MoreBMF meeting explores $25 million Build Back Better grant projects
At the March 15 meeting the NCBIO Biomanufacturers Forum, attendees received updates on the $25 million Build Back Better Regional Challenge grant awarded in the fall. In September, a statewide coalition of public and private partner organizations and institutions led by NC Biotech and including NCBIO received the award from the U.S. Economic Development Administration’s Build Back Better Regional Challenge. The grant will support a number of life sciences workforce initiatives collectively called Accelerate NC.
Read MorePhoto Gallery: 2023 Legislative Reception
Approximately 300 NCBIO member representatives and North Carolina law makers came together Wednesday, March 1, at the NCBIO Legislative Reception held at the NC Museum of History in Raleigh.
Read MoreCollaboration and statewide support make North Carolina a thriving hub of urgently needed innovation in rare disease.
The rarest day on the calendar is the one that does not even occur in every year: February 29. In 2008, this was designated as Rare Disease Day and since then, the last day of February has been an opportunity to draw attention to, honor and support people living with these conditions.
Read MoreNCBIO reaches quarter-million-dollar goal for life sciences scholarships
With a significant gift from Amgen, NCBIO has reached its goal of raising $250,000 to create a scholarship fund at the NC Community College Foundation for students pursuing degrees and certifications in the life sciences. The total amount of gifts and pledges now stands at approximately $260,000.
Read MoreQ&A with the NCBIO Clinical Research Forum panel explores clinical trial barriers
An expert panel explored the current state of clinical trial participation at the NCBIO Clinical Research Forum held Tuesday, Nov. 29. Panelists talked about ways to lower the barriers that stop patients from participating in clinical trials and discussed strategies for achieving diversity. They also explored the role of patient advocates and gave special consideration to efforts focused on rare diseases.
Read More2022 Annual Meeting discusses workforce, health equity, investment, locating in NC
The 2022 NCBIO Annual Meeting held Oct. 12 at the NC Biotechnology Center featured expert panels on locating in North Carolina, talent recruitment, financial trends and health equity and disparities. The meeting returned to being fully in person this year after several years of being virtual or offering an online option due to the COVID pandemic.
Read MoreWhere things stand with the TRIPS waiver
The World Trade Organization is considering continuing to waive certain intellectual property rights on COVID-19 diagnostics and therapeutics, following a recent decision to do the same for vaccines.
Read MoreExpanding COVID IP waiver would harm small, medium enterprises, CSBA says
Every member of the Council of State Bioscience Associations signed a letter to President Joe Biden expressing serious concerns with the proposed expansion of IP protections for COVID technology.
Read More